CSL Limited CSL
ASXPharmaceuticalsFinancials to Jun 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| $B | Jun '25 | Jun '26 |
|---|---|---|
| Cash | 2.2 | 1.5 |
| Securities | 0.0 | 0.0 |
| Debt | 9.8 | 9.4 |
| Net cash | -7.7 | -7.9 |
| Equity | 19.3 | 14.8 |
- Debt / EBITDA
- –
- Debt / equity
- 0.63×
- Leases (6/30/26)
- $1.5B
- Diluted shares
- 482M
- Book value / share
- $30.70
- Price / book
- 4.5×
- Net cash / share
- −$16.33
- Market cap
- $66.6B
- Enterprise value
- $74.4B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 halves |
|---|---|---|---|
| Revenue growth | 5.5% | +0.7 pts | |
| Operating margin | -57.1% | -76.4 pts | |
| FCF margin | 21.3% | -4.7 pts | |
| Capex / revenue | 8.3% | +1.7 pts | |
| Immunoglobulin sales | $6.2B | +3% | |
| Behring segment gross profit | $5.6B | +0% | |
| Donor satisfaction | 88.0% | – | – |
| Pandemic reservation fees | $183M | +2% | |
| Seasonal influenza vaccine sales | $1.6B | – | – |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About CSL
CSL makes medicines from donated plasma, influenza vaccines and iron and kidney-disease treatments. Behring supplies most revenue and has an established collection and manufacturing chain.
- Supply Chain Control
Controlling plasma collection, fractionation and distribution helps CSL secure supply and trace quality from donor to patient.
- Physical Network Density
A dispersed collection network gives donors local access and takes time to replicate.
- Government Contracting Relationships
Established preparedness contracts and qualified influenza plants make CSL a repeat supplier to governments.
- Oct 26, 2026
CSL named Gordon Naylor as its next chair from 31 March 2027, when Brian McNamee will retire. Carolyn Hewson will become senior independent director.
- Oct 22, 2026
CSL disclosed a Victorian Supreme Court group proceeding concerning its FY2026 disclosures and outlook. CSL denies liability and says it will defend the case.
- Oct 21, 2026
CSL named former ViiV Healthcare CEO Deborah Waterhouse as its next CEO, effective 1 February 2027. Gordon Naylor remains interim CEO until then.
- Oct 8, 2026
CSL agreed to switch its US plasma collection centres to Haemonetics’ latest platform, with rollout expected by the end of 2027. Terumo will support the transition from its Rika system.
- Oct 5, 2026
CSL agreed to pay Alentis US$355 million upfront and fund specified lixudebart trials for a 55% share of eventual global profits, adding a potential kidney and liver treatment with clinical and funding risk.
Ownership
Go deeper on CSL
- Compare stock research toolsFundamentals, valuation and screening platforms for CSL.19 tools
- See CSL's price chartNo price chart here yet. See price history and indicators.17 tools
- Read CSL's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | Change 2017–26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share ($) | ||||||||||||
| Revenue | 15.22 | 17.44 | 18.81 | 20.08 | 22.60 | 22.47 | 27.51 | 30.50 | 32.00 | 32.78 | +8.9%/yr | |
| Cash flow | 2.73 | 4.19 | 3.62 | 5.46 | 7.94 | 5.59 | 5.38 | 5.70 | 7.32 | 7.29 | +11.5%/yr | |
| Earnings | 2.93 | 3.81 | 4.23 | 4.61 | 5.21 | 4.80 | 4.53 | 5.45 | 6.17 | -5.35 | – | |
| Free cash flow | 0.85 | 2.00 | 0.79 | 2.46 | 4.28 | 2.94 | 1.88 | 3.11 | 5.27 | 4.64 | +20.8%/yr | |
| Capex | 1.89 | 2.19 | 2.83 | 3.00 | 3.65 | 2.65 | 3.50 | 2.59 | 2.05 | 2.65 | +3.9%/yr | |
| Dividends | 1.32 | 1.48 | 1.78 | 1.94 | 2.10 | 2.21 | 2.24 | 2.46 | 2.74 | 2.93 | +9.3%/yr | |
| Book value | 6.93 | 8.99 | 11.57 | 14.33 | 18.37 | 31.01 | 32.62 | 35.79 | 39.77 | 30.70 | +18.0%/yr | |
| Diluted shares (M) | 456 | 454 | 454 | 456 | 456 | 470 | 484 | 485 | 486 | 482 | +0.6%/yr | |
| Totals ($B) | ||||||||||||
| Revenue | 6.9 | 7.9 | 8.5 | 9.2 | 10.3 | 10.6 | 13.3 | 14.8 | 15.6 | 15.8 | +9.6%/yr | |
| Operating income | 1.8 | 2.4 | 2.5 | 2.7 | 3.1 | 2.9 | 3.1 | 3.8 | 4.1 | -3.7 | – | |
| Net income | 1.3 | 1.7 | 1.9 | 2.1 | 2.4 | 2.3 | 2.2 | 2.6 | 3.0 | -2.6 | – | |
| Free cash flow | 0.4 | 0.9 | 0.4 | 1.1 | 2.0 | 1.4 | 0.9 | 1.5 | 2.6 | 2.2 | +21.5%/yr | |
| Buybacks | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | +9.7%/yr | |
| Dividends | 0.6 | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.1 | 1.2 | 1.3 | 1.4 | +9.9%/yr | |
| Net cash | -3.1 | -3.5 | -4.0 | -3.8 | -2.8 | 2.2 | -9.0 | -8.9 | -7.7 | -7.9 | −$4.8B | |
| Margins & returns (%) | ||||||||||||
| Gross margin | 52.1 | 55.4 | 56.0 | 57.1 | 56.7 | 54.3 | 51.3 | 51.8 | 51.9 | 51.1 | -1.0 pts | |
| Operating margin | 25.5 | 30.1 | 29.3 | 29.7 | 30.4 | 27.7 | 23.1 | 25.8 | 26.6 | -23.3 | -48.8 pts | |
| Net margin | 19.3 | 21.8 | 22.5 | 23.0 | 23.0 | 21.3 | 16.5 | 17.9 | 19.3 | -16.3 | -35.6 pts | |
| FCF margin | 5.6 | 11.5 | 4.2 | 12.2 | 19.0 | 13.1 | 6.8 | 10.2 | 16.5 | 14.1 | +8.6 pts | |
| ROIC | 22.9 | 25.3 | 22.0 | 21.4 | 22.7 | 19.1 | 10.0 | 11.8 | 12.4 | -13.2 | -36.0 pts | |
| Return on equity | 42.3 | 42.4 | 36.5 | 32.2 | 28.3 | 15.5 | 13.9 | 15.2 | 15.5 | -17.4 | -59.7 pts | |
| R&D % of revenue | 9.6 | 8.9 | 9.7 | 10.1 | 9.7 | 10.9 | 9.5 | 9.7 | 8.7 | 7.7 | -1.9 pts | |
| Stock pay % of revenue | 0.2 | 0.4 | 0.6 | 0.9 | 0.9 | 1.1 | 1.0 | 1.1 | 1.0 | 1.1 | +0.9 pts | |
| Capex % of revenue | 12.4 | 12.5 | 15.0 | 14.9 | 16.2 | 11.8 | 12.7 | 8.5 | 6.4 | 8.1 | -4.3 pts | |
Change uses 2017 and 2026 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2017 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- durable
- Trajectory
- stable
- Pricing power
- moderate
- CSL Behring72.1%2 claims
- CSL Seqirus12.9%1 claim
- CSL Vifor15.1%Not scored: evidence insufficient
Moat claims
- Applies to
- CSL Behring
- Confidence
- Durability
- durable
- Trajectory
- stableas of Jun 30, 2026
Controlling plasma collection, fractionation and distribution helps CSL secure supply and trace quality from donor to patient. Replicating the chain takes capital and validated manufacturing processes. It protects CSL against smaller entrants; Takeda and Grifols already operate integrated systems.
FY2026 immunoglobulin sales were US$6.248 billion and flat at constant currency; collection cost per litre continued to fall, but Horizon 2 still needs clinical evidence before its yield advantage can reach patients.
- Immunoglobulin sales$6.2B+3%
- Behring segment gross profit$5.6B+0%
- Rivals expand donor networks and fractionation capacity, increasing competition for inputs and tenders.
- Donor fees, labour costs or collection restrictions raise the cost of the critical input.
- Reimbursement cuts and non-plasma alternatives reduce the revenue earned from each litre.
- Horizon 2 approval or construction takes longer than planned.
- Applies to
- CSL Behring
- Confidence
- Durability
- durable
- Trajectory
- stableas of Jun 30, 2026
A dispersed collection network gives donors local access and takes time to replicate. The advantage depends on repeat donations and centre productivity, not simply the number of sites. CSL says donors have a choice of provider and is closing underperforming centres; evidence supports an established network but does not show dominant local density.
CSL reported 88% donor satisfaction on a new FY2026 survey and continued centre rationalisation; the footprint remains useful, but neither survey changes nor closures establish a widening density advantage.
- Behring segment gross profit$5.6B+0%
- Donors willing to donate again93.0%-1.0 pts
- Donor satisfaction88.0%
- Nearby rivals offer better compensation or a faster donation experience.
- Underused centres leave fixed costs spread over fewer donations.
- Health or regulatory restrictions interrupt the ability to collect locally.
- Applies to
- CSL Seqirus
- Confidence
- Durability
- durable
- Trajectory
- stableas of Jun 30, 2026
Established preparedness contracts and qualified influenza plants make CSL a repeat supplier to governments. Capacity reservation fees help fund readiness between outbreaks. This is a procurement and reliability advantage, while contracts remain subject to renewal and public budgets.
Pandemic reservation fees reached US$183 million in FY2026 and government partnerships expanded, while the fees fell 1% at constant currency; relationships endure without evidence of a step-change in pricing power.
- Pandemic reservation fees$183M+2%
- Seasonal influenza vaccine sales$1.6B
- FLUAD vaccine sales$968M+7%
- FLUCELVAX vaccine sales$503M+6%
- Contracts expire, are retendered or lose funding.
- Lower seasonal vaccination reduces plant utilisation and weakens the economics of readiness.
- A competing platform supplies faster or more effective protection.
Profile change log
- Nov 10, 2026 · business change
CSL named Gordon Naylor as its next chair from 31 March 2027, when Brian McNamee will retire. Carolyn Hewson will become senior independent director.
- Nov 10, 2026 · business change
CSL disclosed a Victorian Supreme Court group proceeding concerning its FY2026 disclosures and outlook. CSL denies liability and says it will defend the case.
- Nov 10, 2026 · business change
CSL named former ViiV Healthcare CEO Deborah Waterhouse as its next CEO, effective 1 February 2027. Gordon Naylor remains interim CEO until then.
- Nov 10, 2026 · business change
CSL agreed to switch its US plasma collection centres to Haemonetics’ latest platform, with rollout expected by the end of 2027. Terumo will support the transition from its Rika system.
- Oct 6, 2026 · business change
CSL agreed to pay Alentis US$355 million upfront and fund specified lixudebart trials for a 55% share of eventual global profits, adding a potential kidney and liver treatment with clinical and funding risk.
- Oct 6, 2026 · business change
CSL disclosed US$7.923 billion of FY2026 restructuring and impairment expenses, a US$2.579 billion shareholder loss and expected Vifor revenue decline of about 25% in FY2027. The reset confirms weaker returns on acquired drugs and some manufacturing assets.
- Oct 6, 2026 · business change
The European Commission revoked Tavneos authorisation after the supporting trial proved unreliable, removing a Vifor renal medicine from EU markets.
- Oct 6, 2026 · business change
CSL announced Horizon 2 clinical work expected to start in mid-2027 after regulator discussions, leaving its next major plasma-yield improvement dependent on additional clinical evidence.
- Oct 6, 2026 · business change
Gordon Naylor became interim CEO after Paul McKenzie retired, placing the restructuring and commercial recovery under new leadership.
- Oct 6, 2026 · business change
CSL sold the Ruide Chinese plasma business for US$185 million, reducing its directly owned local collection and fractionation footprint.
- Oct 6, 2026 · business change
CSL completed the Vifor acquisition, adding iron and renal medicines and a minority-owned dialysis partnership. FY2023 therefore includes a larger business than FY2022.
- Oct 6, 2026 · analyst revision
All three moat claims now have current evidence and stable trajectories. Vifor has insufficient evidence for a segment-wide moat after the sourced generic, reimbursement and regulatory losses. The debate, interim management and linked market profiles now explain these limits.
- Oct 6, 2026 · analyst revision
Segment profit shares were removed because central costs are excluded from segment results. The plasma-network claim was reduced from strength 4 and confidence 4 to 3 and 3: current evidence supports a useful footprint, without verified dominant local density or a peer unit-cost advantage.
Industry & peers
Peer map
Peers appear on the map as their numbers are collected.
Global plasma-derived therapies
Medicines fractionated from donated human plasma, including immunoglobulins, albumin, coagulation factors and specialty proteins. This excludes recombinant proteins, monoclonal antibodies and gene therapies; those also contribute to CSL Behring revenue.
- CSL Behring
- Grifols
- Takeda
- Octapharma
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| CSL | 79 | 51.1% | -23.3% | |
| Industry median | 17 | 69 | 73.1% | 21.8% |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Long-term immune replacement and neurological treatment create repeat demand. Better diagnosis expands the treated population even in a weak economy.
- Home subcutaneous administration and more convenient dosing can improve uptake and retain patients, if clinical results and reimbursement remain competitive.
- Faster collection and higher protein yield can increase output from a scarce biological input. Manufacturing validation determines when a process improvement becomes saleable supply.
- Insurance access and hospital budgets determine how unmet medical need becomes orders. Emerging-market access can expand volumes while lowering realised prices.
- Paid US donors are a concentrated input source. Competition for donors, wage inflation, collection restrictions and public-health interruptions can raise cost or reduce supply.
- New fractionation capacity from established rivals can increase tender competition. Other integrated producers already possess the main collection and manufacturing capabilities.
- Non-plasma therapies can replace immunoglobulin in some neurological indications and reduce demand growth for particular products.
- US reimbursement changes and Chinese albumin cost controls can cut realised price and channel orders even when underlying patient need is stable.
- Regulatory approvals, quality failures and cold-chain interruptions can delay output. Currency translation is material for global producers; higher financing and energy costs increase the cash needed to expand plants.
Bulls & bears
Can Behring restore profitable plasma growth fast enough to offset Vifor decline and fund new manufacturing and drug development without another large loss of invested capital?
Arguments
What to watch
- 1Immunoglobulin revenue, underlying patient demand and channel inventory
- 2Behring segment gross profit, reported cost per litre and manufacturing yield
- 3Iron and nephrology revenue after Velphoro reimbursement expiry
- 4Operating cash flow, PPE and intangible-asset cash spending
- 5Horizon 2 trial and approval milestones, and lixudebart trial results
Next check: 10 February 2027 half-year results for plasma recovery and the first outlook after Velphoro TDAPA expiry.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 79/100 by <a href="https://www.findmymoat.com/stocks/XASX:CSL">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.